Today@Dal

The Canadian Center for Vaccinology is looking for participants age 9-15 for a clinical trial to evaluate the safety and effectiveness of mRNA-1647 vaccine for Cytomegalovirus (CMV). 

The main goals of this study are:

• To see if the study vaccine can prevent CMV infection in participants who have not been previously infected with CMV
• To understand the safety (side effects) of the study vaccine
• To see if the study vaccine results in participants making antibodies to CMV

About CMV

CMV is a leading cause of birth defects around the world and is the number one infection that causes birth defects in the U.S. CMV is a common viral infection that usually goes unnoticed or only causes mild symptoms in most people. But if a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. This can cause her child to have long-term disability due to birth defects, including hearing loss, or even death in very severe cases. Currently, there is no approved vaccine against the virus.

Who can join the clinical trial?

• Youth between 9 and 15 years of age
• In good health
• Not pregnant or planning on becoming pregnant within the next 9 months

What's involved:

This study has 12 clinic visits and approximately 11 safety telephone calls over approximately 18 months. There are 3 study injections in the first 6 months. Participants are compensated financially for their time.

Contact:

Krystal Lariviere, Research Coordinator
Phone: 902-470-6574
Email: Krystal.Lariviere@iwk.nshealth.ca

Learn more.